|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine.
|
16278395 |
2005 |
|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Somatic mutations of FGFR3 have been identified in bladder cancer, multiple myeloma, and other neoplasms.
|
16778799 |
2006 |
|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Activating mutations of FGFR3 are a common and early event in bladder cancer.
|
25223521 |
2015 |
|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Analysing only previously reported point mutations, TERT mutations were found in 55% of patients with bladder cancer (independent of stage), FGFR3 mutations in 30% of patients with bladder cancer, PIK3CA in 14% and TP53 mutations in 12% of patients with bladder cancer.
|
26901314 |
2016 |
|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In view of these findings, the authors investigated the incidence of TD mutations in the FGFR3 gene in a large series of bladder carcinomas to clarify their role in the progression of bladder carcinoma.
|
11745189 |
2001 |
|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We conclude that FGFR3 is commonly mutated in bladder carcinoma and only rarely in cervical carcinoma.
|
11466624 |
2001 |
|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We carried out a meta-analysis of published findings for FGFR3 and TP53 mutations in bladder cancer (535 tumours, 6 publications) and additional unpublished data for 382 tumours.
|
23272046 |
2012 |
|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In non-invasive BC, these mutations were related to high risk and grade (p<0.0001) as well as progression to muscle-invasive disease (p=0.01), whereas FGFR3 mutations were observed in low-grade BC (p=0.02) and patients with recurrences (p=0.05).
|
27611947 |
2016 |
|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
FGFR3 and Tp53 mutations have been proposed as defining two alternative pathways in the pathogenesis of transitional bladder cancer.
|
16061860 |
2005 |
|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
PATIENT SUMMARY: We propose that APOBEC-mediated mutagenesis can generate clinically relevant driver mutations even within suboptimal motifs, such as in the case of FGFR3 S249C, one of the most common mutations in bladder cancer.
|
30975452 |
2019 |
|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Oncogenic FGFR3 gene fusions in bladder cancer.
|
23175443 |
2013 |
|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
FGFR3 mutations are common in low-grade BC, while TP53 mutation or loss of RB1 is associated with muscle-invasive BC.
|
26924873 |
2016 |
|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Our results show a link between germline variants, somatic mutations of FGFR3 and risk of UBC.
|
20348956 |
2010 |
|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Search terms included 'FGFR3 genomic alterations' and 'urothelial cancer' or 'bladder cancer'.
|
27271022 |
2016 |
|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We analyzed the possible prognostic value of the recently discovered fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer.
|
11245416 |
2001 |
|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The detection of FGFR3 mutations in FUH further supports the role of this lesion as precursor of papillary bladder cancer.
|
16570285 |
2006 |
|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
1-tert-butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea (PD173074), a selective tyrosine kinase inhibitor of fibroblast growth factor receptor-3 (FGFR3), inhibits cell proliferation of bladder cancer carrying the FGFR3 gene mutation along with up-regulation of p27/Kip1 and G1/G0 arrest.
|
19955487 |
2010 |
|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
When we examined detailed data on a prevalent occupational exposure associated with increased bladder cancer risk, straight metalworking fluids, we also observed statistically significant additive interaction for rs798766 (TMEM129-TACC3-FGFR3, P interaction = .02), with the interaction more apparent in patients with tumors positive for FGFR3 expression.All statistical tests were two-sided.
|
26374428 |
2015 |
|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Recent developments in the field of molecular mutational pathway analyses based on next generation sequencing technology together with classic data derived from the description of mutations in the FGFR3 (fibroblast growth factor receptor 3) gene, mutations on TP53 gene, and cDNA technology profiling data gives support to a differentiated taxonomy of bladder cancer.
|
25654736 |
2015 |
|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The aim of this review was to overview the outcomes of different mutations in FGFR3 receptor in the context of BC.
|
26542242 |
2015 |
|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We assessed the performance of associating a FGFR3 mutation assay and a DNA methylation analysis to improve bladder cancer detection and to predict disease recurrence of NMIBC patients.
|
27586786 |
2016 |
|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The two most important developments are the identification of a mutation in the fibroblast growth factor receptor 3 gene in more than 50% of urothelial carcinomas and the discovery of cDNA profiles characteristic of different subsets of bladder cancer.
|
19031931 |
2009 |
|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Plasma 25-hydroxyvitamin D(3) and bladder cancer risk according to tumor stage and FGFR3 status: a mechanism-based epidemiological study.
|
23108201 |
2012 |
|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The FGFR3<sup>S249C</sup> mutation may therefore be used as a predictor of chemosensitivity in patients with BCa.
|
31316618 |
2019 |
|
Carcinoma of bladder
|
0.500 |
GeneticVariation
|
disease |
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |